As reported by the House Committee on Energy and Commerce on May 24, 2024
By Fiscal Year, Millions of Dollars
2024
2024-2029
2024-2034
Direct Spending (Outlays)
0
0
0
Revenues
0
0
0
Increase or Decrease (-) in the Deficit
0
0
0
Spending Subject to Appropriation (Outlays)
0
1,156
1,375
Increases net direct spending in any of the four consecutive 10-year periods beginning in 2035?
No
Statutory pay-as-you-go procedures apply?
No
Mandate Effects
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2035?
No
Contains intergovernmental mandate?
No
Contains private-sector mandate?
No
Summary
H.R. 3916 would reauthorize the appropriation of $275 million each year from 2025 to 2029 for the National Breast and Cervical Cancer Early Detection Program, which is administered by the Centers for Disease Control and Prevention (CDC). Under the program, CDC provides grants to states to support access to screening, diagnosis, and treatment of breast and cervical cancer. The bill also would expand the eligible purposes for those grants and amend the program’s evaluation and reporting requirements. In 2024, CDC allocated $235.5 million for the program.
